The Claim
In obese adults with type 2 diabetes, six months of weekly semaglutide treatment is associated with a 21% reduction in plasma FABP4 levels and an 81% increase in neutrophil CD88 expression.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese adults with type 2 diabetes, taking semaglutide once a week for six months is linked to a 21% decrease in a specific fat-related protein in the blood and an 81% increase in a marker on immune cells called neutrophils.
See the scientific wording
In obese adults with type 2 diabetes, six months of weekly semaglutide treatment is associated with a 21% reduction in plasma FABP4 levels and an 81% increase in neutrophil CD88 expression, suggesting modulation of adipose tissue inflammation and complement-mediated immune responses linked to atherosclerosis.
Semaglutide lowers fat tissue inflammation by reducing a protein called FABP4 that activates immune cells. This causes neutrophils to become less sticky and less likely to damage blood vessels. At the same time, semaglutide increases a receptor on neutrophils called CD88, which helps these cells clear a harmful inflammatory signal called C5a. Together, these changes reduce chronic inflammation in blood vessels and slow the development of artery-clogging plaques.
What the research says
1 studyThis study found that a diabetes weight-loss drug called semaglutide lowered a fat-related inflammation marker by 21% and boosted a immune cell signal by 81% in obese diabetic patients after six months — exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.